On August 2, 2021 Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, reported that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually on August 10, 2021 (Press release, Cyteir Therapeutics, AUG 2, 2021, View Source [SID1234585545]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

12th Annual Wedbush PacGrow Healthcare Virtual Conference

Date: Tuesday, August 10

Time: 11:30 AM EDT

Panel: Synthetic Lethal (Weapon)

A live webcast of the Wedbush panel discussion will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

On August 2, 2021 Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, reported its continued collaboration with the Melanoma Research Foundation (MRF), a non-profit organization leading the melanoma community to transform melanoma from one of the deadliest cancers to one of the most treatable through research, education and advocacy (Press release, Castle Biosciences, AUG 2, 2021, View Source [SID1234585544]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MRF Miles for Melanoma and 2021 Galas:

The MRF Miles for Melanoma 5K run/walks are community events held across the United States, both virtually and in-person, to raise funds that support critical research for viable melanoma treatments. Participants include melanoma patients, survivors, caregivers and supporters. Castle Biosciences is a sponsor of the upcoming events taking place in Cleveland, St. Paul, Minn., Philadelphia, Boston and San Francisco.

Additionally, Castle Biosciences is a sponsor of the 2021 MRF galas, taking place in Chicago, Denver and New York, in celebration of courageous melanoma survivors and those in the medical community who are making a difference in the fight against melanoma through exemplary patient care, cutting-edge research or scientific leadership.

"The important work of the MRF to accelerate medical research while advocating for the melanoma community would not be possible without the generous support of corporate sponsors like Castle Biosciences," said Kyleigh LiPira, M.B.A., chief executive officer of the MRF. "We are grateful for their partnership and applaud their commitment to keeping patients at the forefront of their business."

"At Castle, we are committed to improving the lives of patients with skin cancer, and it is at the core of everything we do," said Derek Maetzold, president and chief executive officer of Castle Biosciences. "So, we are proud to further our collaboration with the Melanoma Research Foundation. Their important work in the areas of research, advocacy and education is critical for patients living with melanoma and their families."

On August 2, 2021 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021 (Press release, Biodesix, AUG 2, 2021, View Source [SID1234585543]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Canaccord Genuity 41st Annual Growth Conference

Date: Thursday, August 12, 2021
Time: 12:30 PM ET

The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company’s website at www.biodesix.com.

On August 2, 2021 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the Company will release second quarter 2021 financial results after market close on Monday, August 9, 2021 (Press release, Atara Biotherapeutics, AUG 2, 2021, View Source [SID1234585542]). Following the release, the Company will host a live conference call and webcast at 4:30 p.m. EDT to discuss the Company’s financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Analysts and investors can participate in the conference call by dialing 877-407-8291 for domestic callers and 201-689-8345 for international callers, using the conference ID 13720150. A live audio webcast can be accessed by visiting the Investors & Media – News & Events section of atarabio.com. An archived replay will be available on the Company’s website for 30 days following the live webcast.

On August 2, 2021 ChemoCentryx, Inc., (Nasdaq: CCXI), reported that the Company’s second quarter 2021 financial results will be released after market close on Monday, August 9, 2021 (Press release, ChemoCentryx, AUG 2, 2021, View Source [SID1234585541]). ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2021 to discuss these results and to answer questions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 2164528. A live and archived audio webcast can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. The archived webcast will remain available on the Company’s website for fourteen (14) days following the call.